Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Bridging the gap between histopathology and molecular pathology
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Subscribe To Our Newsletter & Stay Updated
